Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
27 juin 2023 16h05 HE
|
Rezolute, Inc.
Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025 Conference call scheduled today at 4:30 p.m. ET REDWOOD CITY, Calif., June 27, 2023 ...
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
11 mai 2023 16h05 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
23 mars 2023 16h50 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
08 mars 2023 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the...
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
10 févr. 2023 16h05 HE
|
Rezolute, Inc.
Initiated Phase 2 proof-of-concept study of RZ402 Anticipate initiation of global Phase 3 clinical study for RZ358 in mid 2023 REDWOOD CITY, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Rezolute,...
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
15 déc. 2022 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
09 nov. 2022 16h05 HE
|
Rezolute, Inc.
Phase 2 proof-of-concept study of RZ402 expected to be initiated by the end of this year REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage...
Rezolute to Present at the Jefferies London Healthcare Conference
01 nov. 2022 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
20 oct. 2022 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress
15 sept. 2022 16h05 HE
|
Rezolute, Inc.
Announced a $130 million registered direct offering and concurrent private placement priced at-the-market Late-breaking oral presentation from Phase 2b RIZE study of RZ358 presented at ESPE 2022 ...